Market Closed -
OTC Markets
10:19:53 10/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.0008
USD
|
+14.29%
|
|
-61.90%
|
-83.67%
|
Fiscal Period: Giugno |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
91.5
|
38.1
|
120.8
|
93.48
|
14.64
|
10.37
|
Enterprise Value (EV)
1 |
91.1
|
40.32
|
117.2
|
85.16
|
12.12
|
9.574
|
P/E ratio
|
-5.21
x
|
-3.74
x
|
-20.2
x
|
-6
x
|
-2.22
x
|
-3.19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
28,55,85,579
x
|
-
|
81,32,71,167
x
|
-
|
EV / Revenue
|
-
|
-
|
27,71,64,775
x
|
-
|
67,33,26,722
x
|
-
|
EV / EBITDA
|
-6.82
x
|
-6.8
x
|
-27.5
x
|
-9.86
x
|
-1.9
x
|
-3.73
x
|
EV / FCF
|
-15
x
|
-7.88
x
|
-48
x
|
-9.47
x
|
-3.35
x
|
-10.3
x
|
FCF Yield
|
-6.66%
|
-12.7%
|
-2.08%
|
-10.6%
|
-29.8%
|
-9.73%
|
Price to Book
|
-44.7
x
|
-9.21
x
|
91.7
x
|
12.5
x
|
3.3
x
|
5.09
x
|
Nbr of stocks (in thousands)
|
1,55,091
|
2,03,718
|
2,98,278
|
4,33,799
|
4,72,222
|
5,18,348
|
Reference price
2 |
0.5900
|
0.1870
|
0.4050
|
0.2155
|
0.0310
|
0.0200
|
Announcement Date
|
11/09/18
|
30/09/19
|
14/09/20
|
27/09/21
|
28/09/22
|
28/09/23
|
Fiscal Period: Giugno |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.423
|
-
|
0.018
|
-
|
EBITDA
1 |
-13.37
|
-5.926
|
-4.262
|
-8.637
|
-6.376
|
-2.566
|
EBIT
1 |
-13.78
|
-6.297
|
-4.635
|
-9.015
|
-6.758
|
-2.939
|
Operating Margin
|
-
|
-
|
-1,095.74%
|
-
|
-37,544.44%
|
-
|
Earnings before Tax (EBT)
1 |
-16.36
|
-8.681
|
-6.648
|
-13.87
|
-7.041
|
-3.168
|
Net income
1 |
-16.36
|
-8.681
|
-6.648
|
-13.87
|
-7.041
|
-3.168
|
Net margin
|
-
|
-
|
-1,571.63%
|
-
|
-39,116.67%
|
-
|
EPS
2 |
-0.1132
|
-0.0500
|
-0.0201
|
-0.0359
|
-0.0140
|
-0.006263
|
Free Cash Flow
1 |
-6.065
|
-5.114
|
-2.44
|
-8.995
|
-3.618
|
-0.9315
|
FCF margin
|
-
|
-
|
-576.92%
|
-
|
-20,097.92%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/09/18
|
30/09/19
|
14/09/20
|
27/09/21
|
28/09/22
|
28/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
2.22
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.4
|
-
|
3.56
|
8.32
|
2.52
|
0.79
|
Leverage (Debt/EBITDA)
|
-
|
-0.375
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-6.06
|
-5.11
|
-2.44
|
-9
|
-3.62
|
-0.93
|
ROE (net income / shareholders' equity)
|
905%
|
276%
|
499%
|
-309%
|
-115%
|
-93.6%
|
ROA (Net income/ Total Assets)
|
-110%
|
-74.3%
|
-43.6%
|
-47.9%
|
-34.2%
|
-20.5%
|
Assets
1 |
14.87
|
11.68
|
15.25
|
28.99
|
20.57
|
15.43
|
Book Value Per Share
2 |
-0.0100
|
-0.0200
|
0
|
0.0200
|
0.0100
|
0
|
Cash Flow per Share
2 |
0.0100
|
0
|
0.0200
|
0.0200
|
0.0100
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/09/18
|
30/09/19
|
14/09/20
|
27/09/21
|
28/09/22
|
28/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -83.67% | 423K | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|